Prudential Financial Inc. Buys 128,525 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Prudential Financial Inc. lifted its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 30.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 553,424 shares of the biopharmaceutical company's stock after purchasing an additional 128,525 shares during the period. Prudential Financial Inc. owned 0.46% of Catalyst Pharmaceuticals worth $11,550,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. grew its holdings in Catalyst Pharmaceuticals by 4.9% in the 4th quarter. Vanguard Group Inc. now owns 8,431,094 shares of the biopharmaceutical company's stock valued at $175,957,000 after buying an additional 390,116 shares during the last quarter. LPL Financial LLC increased its position in Catalyst Pharmaceuticals by 38.0% during the fourth quarter. LPL Financial LLC now owns 57,983 shares of the biopharmaceutical company's stock worth $1,210,000 after acquiring an additional 15,961 shares during the period. KLP Kapitalforvaltning AS acquired a new position in Catalyst Pharmaceuticals during the 4th quarter valued at $772,000. Sei Investments Co. boosted its holdings in Catalyst Pharmaceuticals by 14.6% in the 4th quarter. Sei Investments Co. now owns 116,318 shares of the biopharmaceutical company's stock valued at $2,428,000 after purchasing an additional 14,849 shares during the period. Finally, American Century Companies Inc. boosted its holdings in Catalyst Pharmaceuticals by 18.3% in the 4th quarter. American Century Companies Inc. now owns 157,409 shares of the biopharmaceutical company's stock valued at $3,285,000 after purchasing an additional 24,395 shares during the period. 79.22% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Catalyst Pharmaceuticals Trading Down 1.6 %

Catalyst Pharmaceuticals stock traded down $0.38 during mid-day trading on Tuesday, hitting $23.87. The stock had a trading volume of 609,163 shares, compared to its average volume of 1,112,590. The stock has a market capitalization of $2.90 billion, a PE ratio of 20.23, a P/E/G ratio of 3.31 and a beta of 0.84. Catalyst Pharmaceuticals, Inc. has a 12 month low of $14.47 and a 12 month high of $26.16. The stock has a 50-day simple moving average of $22.69 and a two-hundred day simple moving average of $21.86.

Insider Transactions at Catalyst Pharmaceuticals

In related news, insider Gary Ingenito sold 44,904 shares of the company's stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total value of $991,929.36. Following the completion of the sale, the insider now owns 68,873 shares in the company, valued at approximately $1,521,404.57. This represents a 39.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Brian Elsbernd sold 62,975 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the transaction, the insider now directly owns 188,564 shares in the company, valued at $4,333,200.72. The trade was a 25.04 % decrease in their position. The disclosure for this sale can be found here. 11.00% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

CPRX has been the topic of a number of recent research reports. StockNews.com raised Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Friday, February 28th. Robert W. Baird increased their price objective on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an "outperform" rating in a research note on Monday, March 3rd. Bank of America reaffirmed a "buy" rating and issued a $30.00 target price on shares of Catalyst Pharmaceuticals in a report on Thursday, January 9th. HC Wainwright reaffirmed a "buy" rating and set a $35.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. Finally, Stephens restated an "overweight" rating and set a $33.00 price target on shares of Catalyst Pharmaceuticals in a research report on Thursday, February 27th. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Buy" and an average target price of $32.29.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.